Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology

Molecular BioSystems

Volumn 7, Issue 1, 2011, Pages 59-66

  Robers, Matthew B ^a   Loh, Christine ^b   Carlson, Coby B ^a   Yang, Hongying ^b   Frey, Elizabeth A ^a   Hermanson, Spencer B ^a   Bi, Kun ^a  

^a Life Technologies   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2,3,4,9 TETRAHYDRO 1H CARBAZOLE 1 CARBOXAMIDE; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; CARBAZOLE DERIVATIVE; HISTONE DEACETYLASE; HYDROXAMIC ACID; PROTEIN P53; SIRTUIN 1; TRICHOSTATIN A;

ACETYLATION; ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; IMMUNOASSAY; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; BLOTTING, WESTERN; CARBAZOLES; CELL LINE, TUMOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOASSAY; MODELS, BIOLOGICAL; PHOSPHORYLATION; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650081320     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/c0mb00026d     Document Type: Article

References (35)

1. M. F. Lavin N. Gueven The complexity of p53 stabilization and activation Cell Death Differ. 2006 3 6 941 950
2. A. Olsson C. Manzl A. Strasser A. Villunger How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ. 2007 14 9 1561 1575
3. N. Tomimatsu C. G. Tahimic A. Otsuki S. Burma A. Fukuhara K. Sato G. Shiota M. Oshimura D. J. Chen A. Kurimasa Ku70/80 modulates ATM and ATR signaling pathways in response to DNA double strand breaks J. Biol. Chem. 2007 282 14 10138 10145
4. L. Feng T. Lin H. Uranishi W. Gu Y. Xu Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity Mol. Cell. Biol. 2005 25 13 5389 5395
5. Y. Tang W. Zhao Y. Chen Y. Zhao W. Gu Acetylation is indispensable for p53 activation Cell 2008 133 4 612 626
6. J. P. Kruse W. Gu Modes of p53 regulation Cell 2009 137 4 609 622
7. J. Yi J. Luo SIRT1 and p53, effect on cancer, senescence and beyond Biochim. Biophys. Acta 2010 1804 8 1684 1689
8. J. M. Solomon R. Pasupuleti L. Xu T. McDonagh R. Curtis P. S. DiStefano L. J. Huber Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. Cell. Biol. 2006 26 1 28 38
9. H. Vaziri S. K. Dessain E. Ng Eaton S. I. Imai R. A. Frye T. K. Pandita L. Guarente R. A. Weinberg hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell 2001 107 2 149 159
10. J. Luo A. Y. Nikolaev S. Imai D. Chen F. Su A. Shiloh L. Guarente W. Gu Negative control of p53 by Sir2alpha promotes cell survival under stress Cell 2001 107 2 137 148
11. D. M. Taylor M. M. Maxwell R. Luthi-Carter A. G. Kazantsev Biological and potential therapeutic roles of sirtuin deacetylases Cell. Mol. Life Sci. 2008 65 24 4000 4018
12. A. D. Napper J. Hixon T. McDonagh K. Keavey J. F. Pons J. Barker W. T. Yau P. Amouzegh A. Flegg E. Hamelin R. J. Thomas M. Kates S. Jones M. A. Navia J. O. Saunders P. S. DiStefano R. Curtis Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 2005 48 25 8045 8054
13. M. H. Aziz M. Nihal V. X. Fu D. F. Jarrard N. Ahmad Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins Mol. Cancer Ther. 2006 5 5 1335 1341
14. C. X. Deng SIRT1, is it a tumor promoter or tumor suppressor? Int. J. Biol. Sci. 2009 5 2 147 152
15. N. Kabra Z. Li L. Chen B. Li X. Zhang C. Wang T. Yeatman D. Coppola J. Chen SirT1 is an inhibitor of proliferation and tumor formation in colon cancer J. Biol. Chem. 2009 284 27 18210 18217
16. S. Lavu O. Boss P. J. Elliott P. D. Lambert Sirtuins - novel therapeutic targets to treat age-associated diseases Nat. Rev. Drug Discovery 2008 7 10 841 853
17. T. Liu P. Y. Liu G. M. Marshall The critical role of the class III histone deacetylase SIRT1 in cancer Cancer Res. 2009 69 5 1702 1705
18. M. B. Robers R. A. Horton M. R. Bercher K. W. Vogel T. Machleidt High-throughput cellular assays for regulated posttranslational modifications Anal. Biochem. 2008 372 2 189 197
19. C. B. Carlson M. B. Robers K. W. Vogel T. Machleidt Development of LanthaScreen™ Cellular Assays for Key Components within the PI3K/AKT/mTOR Pathway J. Biomol. Screening 2009 14 2 121 132
20. K. G. Huwiler T. Machleidt L. Chase B. Hanson M. B. Robers Characterization of serotonin 5-hydroxytryptamine-1A receptor activation using a phospho-extracellular-signal regulated kinase 2 sensor Anal. Biochem. 2009 393 1 95 104
21. M. B. Robers T. Machleidt C. B. Carlson K. Bi Cellular LanthaScreen and beta-lactamase reporter assays for high-throughput screening of JAK2 inhibitors Assay Drug Dev. Technol. 2008 6 4 519 529
22. A. Vazquez E. E. Bond A. J. Levine G. L. Bond The genetics of the p53 pathway, apoptosis and cancer therapy Nat. Rev. Drug Discovery 2008 7 12 979 987
23. H. L. Cheng R. Mostoslavsky S. Saito J. P. Manis Y. Gu P. Patel R. Bronson E. Appella F. W. Alt K. F. Chua Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice Proc. Natl. Acad. Sci. U. S. A. 2003 100 19 10794 10799
24. M. Kruszewski I. Szumiel Sirtuins (histone deacetylases III) in the cellular response to DNA damage - facts and hypotheses DNA Repair 2005 4 11 1306 1313
25. K. T. Howitz K. J. Bitterman H. Y. Cohen D. W. Lamming S. Lavu J. G. Wood R. E. Zipkin P. Chung A. Kisielewski L. L. Zhang B. Scherer D. A. Sinclair Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 2003 425 6954 191 196
26. B. Jung-Hynes M. Nihal W. Zhong N. Ahmad Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J. Biol. Chem. 2009 284 6 3823 3832
27. B. Peck C. Y. Chen K. K. Ho P. Di Fruscia S. S. Myatt R. C. Coombes M. J. Fuchter C. D. Hsiao E. W. Lam SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2 Mol. Cancer Ther. 2010 9 4 844 855
28. M. T. Borra B. C. Smith J. M. Denu Mechanism of human SIRT1 activation by resveratrol J. Biol. Chem. 2005 280 17 17187 17195
29. J. M. Dudek R. A. Horton TR-FRET biochemical assays for detecting posttranslational modifications of p53 J. Biomol. Screening 2010 15 5 569 575
30. K. Vogel Z. Zhong K. Bi B. Pollok Developing assays for drug discovery - where have the advances come from Expert Opin. Drug Discovery 2008 3 115 125
31. B. Jung-Hynes N. Ahmad Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells Cell Cycle 2009 8 10 1478 1483
32. T. A. Kost J. P. Condreay R. S. Ames S. Rees M. A. Romanos Implementation of BacMam virus gene delivery technology in a drug discovery setting Drug Discovery Today 2007 12 9-10 396 403
33. K. Sakaguchi J. E. Herrera S. Saito T. Miki M. Bustin A. Vassilev C. W. Anderson E. Appella DNA damage activates p53 through a phosphorylation- acetylation cascade Genes Dev. 1998 12 18 2831 2841
34. R. Puca L. Nardinocchi A. Sacchi G. Rechavi D. Givol G. D'Orazi HIPK2 modulates p53 activity towards pro-apoptotic transcription Mol. Cancer 2009 8 85
35. R. Ames J. Fornwald P. Nuthulaganti J. Trill J. Foley P. Buckley T. Kost Z. Wu M. Romanos BacMam recombinant baculoviruses in G protein-coupled receptor drug discovery Recept. Channels 2004 10 3-4 99 107